Objective: This study aims to investigate the efficacy and safety of daily drospirenone/17A-estradiol in two lowdose combinations (0.25 mg/0.5 mg and 0.5 mg/0.5 mg, respectively) versus 17A-estradiol (0.3 mg) or placebo in postmenopausal women with moderate to severe vasomotor symptoms.
V asomotor symptoms, including hot flushes (HF), are the most common and troublesome symptoms of menopause. 1 Approximately one-third of women with vasomotor symptoms find these symptoms sufficiently severe to require medical treatment, typically with hormone therapies containing estrogen alone or estrogen combined with progestin. 2 Recent guidelines recognize the need to use the lowest effective dose of hormone therapy, consistent with the treatment goals for each woman. 3<5 The Endocrine Society, in their 2010 scientific statement, provided a comprehensive, rigorously documented, objective, scientific analysis of existing data evaluating the benefits and risks of hormone therapy for postmenopausal women. 5 The statement concluded that lower doses of estrogen are often effective for postmenopausal symptom management and maintenance of bone mineral density. Furthermore, it stated that standard or low-dose therapy given to healthy postmenopausal women does not increase cardiovascular events significantly. 5 The progestin drospirenone (DRSP), in combination with 17A-estradiol (E 2 ), is used as hormone therapy and, in combination with ethinylestradiol, is used as contraceptive. The characteristics of DRSP include a pharmacodynamic profile similar to that of endogenous progesterone. 6 DRSP has a unique aldosterone receptorYblocking activity that attenuates estrogen-induced, aldosterone-mediated water and sodium retention with beneficial antiandrogenic properties. 7, 8 DRSP/E 2 combination therapy (Angeliq) is available worldwide in dose combinations of DRSP 0.5 mg/E 2 1 mg, DRSP 1 mg/E 2 1 mg, and DRSP 2 mg/E 2 1 mg taken orally, continuously, and once daily. Approved indications include the treatment of vasomotor and vulvovaginal atrophy symptoms due to menopause, and the prevention of postmenopausal osteoporosis. The lowdose combination DRSP 0.25 mg/E 2 0.5 mg was approved by the US Food and Drug Administration (FDA) in February 2012 for the treatment of moderate to severe vasomotor symptoms due to menopause. DRSP 0.5, 1, 2, or 3 mg, combined with E 2 1 mg, has demonstrated efficacy for the relief of postmenopausal symptoms, including frequency of HF, for periods up to 1 year. 9<11 DRSP 1 or 2 mg with E 2 1 mg is also efficacious for preventing osteoporosis in postmenopausal women. 12 In addition, DRSP 2 or 3 mg with E 2 1 mg has been shown to reduce blood pressure in postmenopausal women with hypertension, 13<15 which may be explained by the antialdosterone effects of DRSP. 16 Several studies have additionally reported potentially beneficial effects on lipid profile. 12, 14, 17 The efficacy and safety characteristics of DRSP 2 mg combined with E 2 1 mg were recently shown to translate into a significant improvement in the quality of life of postmenopausal women. 18 The dose combination of DRSP/E 2 approved by the US FDA in 2005 for the treatment of vasomotor symptoms in postmenopausal women was DRSP 0.5 mg/E 2 1 mg. The current 12-week, placebo-controlled study was performed, upon the request of the US Regulatory Agency, to characterize the lowest effective dose combination of DRSP/E 2 for the relief of moderate to severe vasomotor symptoms. Two dose combinations (DRSP 0.25 mg/E 2 0.5 mg and DRSP 0.5 mg/E 2 0.5 mg) were compared with placebo, with E 2 0.3 mg monotherapy included as active comparator.
METHODS

Study design
This 12-week, double-blind, randomized, parallel-group, placebo-controlled, phase III study was performed in 79 centers in the United States between March 2007 and November 2008 (ClinicalTrials.gov Identifier: NCT00446199).
The study was approved by the institutional review board at each site and conducted in accordance with ethical principles based on the Declaration of Helsinki and the International Conference on Harmonization Guideline E6: Good Clinical Practice. All women provided a written informed consent form before study entry and had the right to withdraw from the study at any time. Participants could also be withdrawn from the study at any time at the discretion of the investigator.
Study population
Women aged 40 years or older were eligible for study inclusion if they experienced spontaneous amenorrhea for 12 months or more, experienced spontaneous amenorrhea with serum follicle-stimulating hormone levels higher than 40 mIU/mL for 6 months or more, or had undergone bilateral oophorectomy with or without hysterectomy 6 weeks or more previously. Participants experiencing a minimum of 7 to 8 moderate to severe HF per day, or 50 to 60 moderate to severe HF per week, for at least seven consecutive days during the screening period were eligible for the study. The results of breast and mammographic examinations andVin women with intact uterusVtransvaginal ultrasound and endometrial biopsies should be normal at screening.
Exclusion criteria included the use of oral estrogen and/or progestin therapy within 8 weeks, intrauterine progestin therapy within 8 weeks, transdermal estrogen or estrogen/progestin products within 4 weeks, or vaginal hormonal products within 1 week. Progestin implants and estrogen-alone injectable drug therapy within 3 months, and estrogen pellet therapy or progestin injectable drug therapy within 6 months were also prohibited. The presence of a clinically significant disease (including contraindications to hormone therapy) and abnormal laboratory values were further exclusion criteria. Prohibited concomitant medications included additional steroid hormones, anticoagulant agents, antiepileptic agents, antibiotics, and CYP3A4 inhibitors and inducers. Selective serotonin reuptake inhibitors, norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, raloxifene, or tamoxifen were prohibited within 2 weeks of signing an informed consent form. Further medications were prohibited owing to potential interactions with DRSP/E 2 ingredients.
Study medications
Using a randomization number generated by the sponsor's central randomization group, we assigned women to receive one of four treatments in a 1:1:1:1 ratio: DRSP 0.25 mg/E 2 0.5 mg, DRSP 0.5 mg/E 2 0.5 mg, E 2 0.3 mg, or placebo.
The E 2 dose in DRSP/E 2 combinations was selected based on evidence that a dose of 0.5 mg or lower is effective for the long-term treatment of moderate to severe vasomotor symptoms. 19<21 A daily DRSP dose of 0.5 mg has been shown to oppose the development of endometrial hyperplasia induced by E 2 1 mg. 11 The safety of DRSP 0.25 mg, in combination with E 2 0.5 mg, is the subject of a 12-month study. 22 The 0.3-mg dose for E 2 monotherapy was selected to provide serum E 2 levels corresponding to a microdose transdermal treatment with a 1.0-mg Menostar patch 23 and was predicted not to induce significant stimulation of the endometrium, with no need for concomitant progestin use.
All participants received five blister packs, each containing 28 tablets, to provide a total treatment period of three consecutive cycles of 28 days (with two blister packs on reserve). Participants were instructed to take one tablet orally in the morning at approximately the same time each day, with no tablet-free days between cycles. Participants' compliance to treatment was determined by the number of returned blister packs and by the participants' entries on diary cards Blister packs and tablets were indistinguishable in size and color between treatment groups to preserve randomization.
Efficacy evaluations
Women were requested to record the frequency and severity of HF during the treatment period on diary cards on a daily basis. The diary cards were reviewed and collected by the investigator at each visit during the treatment period and at the end of the treatment period.
The four primary efficacy variables were as follows: the absolute change from baseline to week 4 in the weekly frequency of moderate to severe HF, the absolute change from baseline to week 12 in the weekly frequency of moderate to severe HF, the absolute change from baseline to week 4 in the weekly mean daily severity of moderate to severe HF, and the absolute change from baseline to week 12 in the weekly mean daily severity of moderate to severe HF. Severity scoring ranged from 0 (no symptoms), 1 (mild symptoms; sensation of heat without perspiration), 2 (moderate symptoms; sensation of heat with perspiration, able to continue activity), to 3 (severe symptoms; sensation of heat with sweating, causing cessation of activity), in accordance with regulatory guidelines. 24 Secondary efficacy variables included the following: changes in vaginal pH and vaginal maturation index; the proportions of participants with vulvovaginal atrophy and urogenital symptoms; and quality-of-life assessments using the 37-item Women's Health Questionnaire (WHQ). 25 Exploratory efficacy analyses included the self-administered Clinical Global Impressions (CGI) scale 26 and the muscle and joint pain questionnaire on week 12. Assessments were performed at screening or baseline, and on week 12 or at the end of the study.
Safety evaluations
Safety variables included treatment-emergent adverse events (TEAEs), coded using the Medical Dictionary of Regulatory Authorities and categorized by duration, intensity, and relationship to treatment. Laboratory tests, performed at a central laboratory, included standard hematology, serum chemistry, liver enzyme, lipid and carbohydrate metabolism, and urine assessments. Additional safety variables included vital signs, endometrial thickness (by transvaginal ultrasound), endometrial histology (by endometrial biopsy), Papanicolaou test, physical examination, and bleeding profile recorded by participants on daily diary cards (among women with intact uterus). Safety assessments were performed at screening or baseline, and on week 12 or at the end of the study, with the exception of vital signs and adverse events, which were additionally recorded on weeks 4 and 8.
Statistical analyses
Change in the weekly frequency of moderate to severe HF was computed as the difference from baseline in the weekly frequency of moderate to severe HF on week 4 or 12. For weeks with missing data up to 2 days, the weekly total was imputed using the weighted average. If data were missing for more than 2 days in any week, the weekly total was classified as missing, and the nonmissing data of the preceding week were carried forward. For dropouts, the last observed value was carried forward to week 4 or 12.
The mean severity of moderate to severe HF on each day was calculated as: [(2 Â number of moderate HF) + (3 Â number of severe HF)] / (total number of moderate to severe HF). Weekly mean daily severity was calculated by averaging the daily severity of moderate to severe HF.
The primary analysis method for comparing active treatments with placebo was a nonparametric approach using the Wilcoxon/van Elteren test, with stratification by pooled study centers. A secondary analysis method used a parametric approach with an analysis of covariance (ANCOVA) model, with treatment group, center, and baseline value as covariates. For the difference between the adjusted means of the active treatment groups and placebo on ANCOVA, 95% CIs were constructed. The multiplicities of the four primary endpoints and of the comparison of three active treatments with placebo were controlled for by requiring that all primary endpoints be statistically significant for each treatment comparison, as well as by Bonferroni correction, for the three treatment comparisons. Thus, each primary variable was tested at a two-sided significance level of 0.017, yielding an overall two-sided significance level of 5% for the study.
Responder analyses were derived from the minimal clinically important difference analysis for the mean change from baseline in moderate to severe HF, using the CGI scale as an anchor variable. 27 Participants were defined as responders if they experienced a reduction of at least 2.7 moderate to severe HF per day (ie, at least Bminimally improved[) on week 4 and a reduction of at least 5.8 moderate to severe HF per day (ie, at least Bmuch improved[) on week 12.
In secondary efficacy analyses, active treatment groups were compared with placebo at the two-sided 0.05 significance level. No multiplicity adjustment was performed. Continuous secondary efficacy variables were analyzed as for the primary efficacy variables. Categorical secondary efficacy variables and exploratory variables were analyzed by the Cochran-Mantel-Haenszel technique after adjusting for pooled centers. Mean changes in WHQ scores were analyzed with a two-way analysis-of-variance model with terms of treatment and pooled center.
Safety variables were investigated by descriptive statistics. Primary efficacy variables were assessed on the full analysis set (FAS), including participants who had baseline and 1-day postbaseline vasomotor symptom data after starting study medication, and on the per-protocol set (PPS), including participants who had at least 75% overall study drug compliance and no major protocol violations. Secondary efficacy variables were performed on the FAS only. Safety variables were assessed on the safety analysis set (SAF), which included all participants who took at least one dose of study medication.
Based on previous studies, the sample size was calculated to be able to detect a mean (SD) difference of 13 (34) for the mean change in the weekly frequency of moderate to severe HF and a mean (SD) difference of 0.4 (1.0) units for the mean change in the weekly mean daily severity between the lowdose E 2 group and the placebo group on week 12. A sample size of 220 participants per treatment group (including 20% for expected dropouts) would provide 87% power for the mean change in weekly frequency and 90% power for the mean change in the weekly mean daily severity of moderate to severe HF on week 12.
RESULTS
Study population
Of 2,457 women screened, 735 were randomized to receive either DRSP 0.25 mg/E 2 0.5 mg (n = 184), DRSP 0.5 mg/E 2 0.5 mg (n = 183), E 2 0.3 mg (n = 185), or placebo (n = 183; Fig. 1 ). Major reasons for screen failure included inclusion/ exclusion criteria not being met (n = 1,253) and withdrawal of consent (n = 279). The FAS included 710 participants (n = 177, DRSP 0.25 mg/E 2 0.5 mg; n = 178, DRSP 0.5 mg/E 2 0.5 mg; n = 179, E 2 0.3 mg; n = 176, placebo). There were 569 and 726 women in the PPS and SAF, respectively, with equivalent numbers in each treatment group. The major reason for exclusion from the PPS was insufficient compliance with study treatment (n = 121) (ie, women who had G75% overall study drug compliance or who had a major protocol violation).
Baseline demographic and clinical characteristics are described in Table 1 . There were no relevant differences in baseline variables between the treatment groups. Last menstruation occurred at a mean (SD) age of 44.66 (7.55) years, on average 9.36 (8.46) years previously. Almost no participants (0.4%) were currently receiving hormone therapy. Hysterectomy had been performed in 54.4% of participants, and oophorectomy had been performed in 34.4% of participants (bilateral in 77.1% of these cases). The most common concomitant clinical conditions at baseline were hypertension (20.0% of participants) and increased low-density lipoprotein (13.5%); the frequency of both conditions was equivalent across treatment groups. Concomitant medications in the Balimentary tract and metabolism[ class were taken by 52.0% of participants, and in the Bcardiovascular system[ class by 47.3% of participants (Anatomic Therapeutic Chemical classification) during participation in the study.
The planned 12-week study duration, including the intake of study medication, was completed by 635 (86.4%) participants, whereas the remaining 100 (13.6%) either never took or prematurely discontinued study medication (Fig. 1 ). Major reasons for premature discontinuation of study medication included withdrawal of consent (n = 26), adverse events (n = 21), and loss of participants to follow-up (n = 17), without relevant differences between the treatment groups.
The mean (SD) duration of treatment in the SAF was 81.28 (21.04) days, with nearly identical durations in each treatment group. The mean (SD) treatment compliance, based on returned pill counts, was 90.63% (23.50%) across treatment groups.
Efficacy evaluations
All four treatment groups had comparable mean values at baseline with respect to the weekly frequency of moderate to severe HF, ranging from 73.25 (E 2 0.3 mg) to 74.64 (DRSP 0.25 mg/E 2 0.5 mg). Similarly, the mean daily severity score of moderate to severe HF was similar between the groups at baseline, ranging from 2.52 (placebo) to 2.58 (DRSP 0.25 mg/ E 2 0.5 mg).
All active treatments were significantly more effective than placebo in the primary efficacy variables, namely, mean changes in the weekly frequency and weekly mean daily severity of moderate to severe HF on weeks 4 and 12 (Tables 2  and 3 ). The time courses for median changes in the weekly frequency and weekly mean daily severity of moderate to severe HF are shown in Figures 2 and 3 . The two DRSP/E 2 groups first showed a statistically significant difference from placebo in both the frequency and the severity of moderate to severe HF on week 2, which was maintained throughout the study. For E 2 0.3 mg, the difference from placebo in the weekly frequency of moderate to severe HF was statistically significant from week 3 onward, and the difference from placebo in the mean daily severity of moderate to severe HF was significant on week 2 (not week 3) and from week 4 onward.
Although not statistically investigated, the mean changes in the weekly frequency and weekly mean daily severity of moderate to severe HF on week 12 were numerically greater in the DRSP 0.5 mg/E 2 0.5 mg group than in the DRSP 0.25 mg/E 2 0.5 mg group, which in turn showed efficacy greater than that of the E 2 0.3 mg group.
The rates of global response at the end of the trial (using two criteria: a reduction of at least 2.7 moderate to severe HF per day on week 4 and a reduction of at least 5.8 moderate to severe HF per day on week 12) were 62.7%, 75.8%, 49.2%, and 26.7% in the DRSP 0.25 mg/E 2 0.5 mg, DRSP 0.5 mg/E 2 0.5 mg, E 2 0.3 mg, and placebo groups, respectively (P G 0.0001, Fisher's exact test; all active treatment groups vs placebo). Onset of efficacy, defined as the time when 50% or more of the participants reached the first threshold level of response (ie, reduction of 2.7 moderate to severe HF per day) corresponding to at least a minimal improvement reported by the CGI scale, was 2 weeks in the DRSP 0.5 mg/E 2 0.5 mg and E 2 0.3 mg groups, 3 weeks in the DRSP 0.25 mg/E 2 0.5 mg group, and 4 weeks in the placebo group (Fig. 4) .
The mean (SD) decrease in vaginal pH from screening to week 12 or the end of the study was significantly greater in all active treatment groups versus placebo: 0.63 (0.94), 0.63 (0.87), 0.66 (0.97), and 0.06 (0.7) for DRSP 0.25 mg/E 2 0.5 mg, DRSP 0.5 mg/E 2 0.5 mg, E 2 0.3 mg, and placebo, respectively (P G 0.0001, Wilcoxon/van Elteren test). The reduction in percent parabasal cells and the increase in percent superficial cells, using the vaginal maturation index, were significantly higher in all active treatment groups versus placebo (P e 0.0028), with the highest levels of significance in the DRSP/E 2 groups. Only a few women reported moderate to severe urogenital or vulvovaginal atrophy symptoms in addition to HF at baseline, precluding a meaningful statistical analysis of this subgroup.
WHQ scores showed significantly greater improvement in vasomotor symptoms in all active treatment groups versus placebo (P G 0.0001), whereas specific subscale scores were significantly improved in individual DRSP/E 2 groups: anxiety fears (DRSP 0.25 mg/E 2 0.5 mg, P = 0.0086), sleep problems (DRSP 0.25 mg/E 2 0.5 mg, P = 0.0053; DRSP 0.5 mg/E 2 0.5 mg, P G 0.0001), and memory concentration (DRSP 0.5 mg/E 2 0.5 mg, P = 0.0054; ANCOVA). CGI scale responses of Bvery much improved[ or Bmuch improved[ were reported by 81.4% in the DRSP 0.25 mg/E 2 0.5 mg group, 83.7% in the DRSP 0.5 mg/E 2 0.5 mg group, 62.0% in the E 2 0.3 mg group, and 36.7% in the placebo group, representing significant differences in response categories for all active treatments versus placebo (P G 0.0001). In the muscle and joint pain questionnaire, no differences in Barthralgia[ and Bmyalgia[ symptoms were observed between the active treatment groups and the placebo group.
Safety evaluations
A total of 409 participants (56.3%) reported at least one TEAE during the study, including 55.2% of the DRSP 0.25 mg/E 2 0.5 mg group, 61.9% of the DRSP 0.5 mg/E 2 0.5 mg group, 52.2% of the E 2 0.3 mg group, and 56.1% of the placebo group. TEAEs considered by investigators to be related to the study drug were reported in 24.2% (n = 176) of participants overall, including 23.5% of the DRSP 0.25 mg/E 2 0.5 mg group, 28.7% of the DRSP 0.5 mg/E 2 0.5 mg group, 22.5% of the E 2 0.3 mg group, and 22.2% of the placebo group. Serious TEAEs were reported by one participant receiving DRSP 0.25 mg/E 2 0.5 mg (salpingitis), three participants receiving E 2 0.3 mg (oropharyngeal cancer, malignant neoplasm lung, and ovarian cyst with uterine polyp), and one participant in the placebo group (road accident). Rates of TEAEs considered to be related to the study drug and categorized by treatment group are reported in Table 4 .
Twenty-one participants (2.9%) discontinued the study prematurely because of a TEAE, including four (2.2%), seven (3.9%), six (3.3%), and four (2.2%) participants in the DRSP 0.25 mg/E 2 0.5 mg, DRSP 0.5 mg/E 2 0.5 mg, E 2 0.3 mg, and placebo groups, respectively. Headache (n = 4), abdominal pain (n = 3), and hypertension (n = 3) were the most frequently reported TEAEs leading to premature discontinuation.
Mean and median values for standard hematology and serum chemistry assessments were within reference ranges at baseline and on week 12 in all treatment groups, and there were no obvious differences between the groups at any visit. Mean and median values for vital signs (systolic blood pressure, diastolic blood pressure, heart rate, and body weight) were within reference limits in all treatment groups at all visits, with no obvious differences between the groups.
Of 332 women with intact uterus (45.7% of the SAF), 85 (25.6%) had an episode of bleeding/spotting during treatment, including 26 (29.2%), 31 (37.8%), 17 (20.5%), and 11 (14.1%), respectively, in the DRSP 0.25 mg/E 2 0.5 mg, DRSP 0.5 mg/E 2 0.5 mg, E 2 0.3 mg, and placebo groups. Papanicolaou test results were abnormal (ie, low-grade squamous intraepithelial lesion or atypical cells of undetermined significance) in 1 participant (0.5%) at screening and in 24 participants (3.5%) on week 12, including 8 (4.6%), 2 (1.2%), 6 (3.5%), and 8 (4.8%) women in the DRSP 0.25 mg/E 2 0.5 mg, DRSP 0.5 mg/E 2 0.5 mg, E 2 0.3 mg, and placebo groups, respectively. There were no cases of cervical cancer.
DISCUSSION
This 12-week, multicenter, double-blind, randomized, parallelgroup, placebo-controlled study investigated the lowest effective dose of DRSP/E 2 combination for the treatment of moderate to severe vasomotor symptoms in post menopausal women. Both DRSP/E 2 groups investigated (DRSP 0.25 mg/E 2 0.5 mg and DRSP 0.5 mg/E 2 0.5 mg) were effective for the relief of vasomotor symptoms, providing significant improvements versus placebo in the weekly frequency and weekly mean daily severity of moderate to severe HF on both weeks 4 and 12, although the changes in these measures on week 12 were numerically greater in the DRSP 0.5 mg/E 2 0.5 mg group than in the DRSP 0.25 mg/E 2 0.5 mg group.
The DRSP 0.25 mg/E 2 0.5 mg dose combination is concluded to be the lowest effective dose for the treatment of postmenopausal women with moderate to severe vasomotor symptoms. This is based on the following considerations. First, the reduction in the frequency of moderate to severe HF, compared with placebo, was statistically significant from week 2 onward with both DRSP/E 2 combinations. Second, the responder rate, which is also considered to be clinically important (derived here from the empirical minimal clinically important difference 27 ), was only slightly lower in the DRSP 0.25 mg/E 2 0.5 mg group than in the DRSP 0.5 mg/E 2 0.5 mg group (62.7% vs 75.8%, compared with only 26.7% in the placebo group).
Based on the results of this study and on a 1-year safety study of the same dose combination, 22 the US FDA has approved the low-dose formulation DRSP 0.25 mg/E 2 0.5 mg for the treatment of moderate to severe vasomotor symptoms in postmenopausal women with intact uterus. Improvements in secondary efficacy variables contributed to the overall satisfaction of women with the active treatments. The reduction in vaginal pH and the increase in vaginal maturation index were significant in all active treatment groups compared with placebo and can be considered favorable effects on a population that frequently experiences vulvovaginal atrophy symptoms.
Significant efficacy against vasomotor symptoms, as in the current study, has also been reported for low-dose E 2 (0.5 mg) in combination with norethisterone acetate 0.1 or 0.25 mg, 28 for E 2 (0.5 mg), 21 and for microdose E 2 (0.014 mg, transdermal). 29 Onset of efficacy with the 0.5-mg E 2 dose was first observed on week 3 by Gerlinger et al 27 and on week 8 by Notelovitz et al, 21 compared with week 2 for the DRSP/E 2 combinations in the current study, which may indicate a contribution of DRSP to the treatment effect of E 2 , as noted above. The stronger effect of DRSP 0.5 mg/E 2 0.5 mg compared with DRSP 0.25 mg/E 2 0.5 mg on the frequency and severity of moderate to severe HF, as well as the higher responder rate with the higher DRSP dose combination, may support this conclusion. All active treatments were well tolerated. Rates of TEAEs and TEAE-related dropouts were at placebo-equivalent levels in all groups. A low dropout rate is important for statistical validity in a trial and additionally provides a measure of patient acceptability that is relevant to clinical practice. The safety profile was consistent with previous studies of DRSP/ E 2 dose combinations (eg, Schurmann et al, 9 White et al, 13 and Gambacciani et al 18 ). Bleeding rates, as expected, were above placebo levels for all active treatments during this 12-week study. A reduction in bleeding events over time can be predicted during continued DRSP/E 2 therapy. 11 These study findings suggest that the DRSP/E 2 combination may be initiated at the lowest effective dose (ie, DRSP 0.25 mg/E 2 0.5 mg) in eligible women experiencing moderate to severe vasomotor symptoms, with an expected significant response in about two-thirds of individuals. The onset of symptom relief at this dose is rapid (ie, within 2 wk). Higher dose combinations of DRSP/E 2 may be used for women who do not respond to DRSP 0.25 mg/E 2 0.5 mg by week 6 of treatment. This is based on the flattening of the reduction in HF frequency (Fig. 2 ) and the time to reach a significant response ( Fig. 4 ). This recommendation is in line with the current North American Menopause Society position statement recommending that physicians start with the lowest effective dose of hormone therapy for the management of HF in postmenopausal women. 3, 4, 30, 31 
CONCLUSIONS
The lowest dose combination of DRSP/E 2 investigated in this study (DRSP 0.25 mg/E 2 0.5 mg), although offering slightly lower efficacy than the higher dose combination (DRSP 0.5 mg/E 2 0.5 mg), provides clinically relevant improvements in HF relative to placebo. Based on these observations, the dose combination DRSP 0.25 mg/E 2 0.5 mg is concluded to be the lowest effective dose for the treatment of postmenopausal women with moderate to severe vasomotor symptoms.
